ACHL Profile
Achilles Therapeutics plc, a clinical-stage immuno-oncology biopharmaceutical company, focuses on developing precision T cell therapies for the treatment of various solid tumors. The company's lead product candidates include CHIRON, which is currently in Phase I/IIa clinical trials for the treatment of advanced non-small cell lung cancer (NSCLC). This therapy is designed to target specific mutations within a patient's tumor, providing a personalized approach to cancer treatment.
Another key product candidate is THETIS, which is also in Phase I/IIa clinical trials and is aimed at treating metastatic or recurrent melanoma. THETIS utilizes a similar precision T cell approach, aiming to harness the body's immune system to specifically target and destroy cancer cells. Achilles Therapeutics is also advancing its pipeline with therapies for head and neck squamous cell carcinoma, renal cell carcinoma, triple-negative breast cancer, and bladder cancer, addressing a wide range of unmet medical needs in oncology.
The company leverages its proprietary PELEUS™ bioinformatics platform and the VELOS™ manufacturing process to develop and produce its personalized T cell therapies. The PELEUS™ platform is used to identify unique clonal neoantigens present in a patient's tumor, which are then targeted by the engineered T cells. The VELOS™ process ensures the efficient and scalable production of these precision therapies, maintaining high quality and consistency across treatments.
Originally known as Achilles TX Limited, the company rebranded to Achilles Therapeutics plc in February 2021 to reflect its expanding focus and commitment to immuno-oncology. Founded in 2016 and headquartered in London, United Kingdom, Achilles Therapeutics is driven by a mission to revolutionize cancer treatment through innovative and personalized immunotherapies. The company's cutting-edge research, robust clinical pipeline, and strategic collaborations position it at the forefront of the next generation of cancer therapies.
|
